A real-world observational study of treatment patterns and outcomes for patients with neuromyelitis optica spectrum disorders (NMOSD) treated with inebilizumab (UPLIZNA) in Europe

First published 25/03/2024

Last updated 25/03/2024

EU PAS number:

EUPAS1000000084

Study

Planned

Documents

Study protocol

Updated protocol

HZNP-UPL-402 Protocol_v2.0_clean_17Feb2023_redacted.pdf

First published: 22/03/2024

English (1.08 MB - PDF)View document

Study results

Study report

Other information

ENCePP Seal

ENCePP Seal documents

Secondary tabs